Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT07401160·Not applicable·INTERVENTIONAL

Umbilical Cord Drainage to Prevent Postpartum Hemorrhage

OxytocinOtherRecruiting

Status

Recruiting

Phase

Not applicable

Enrollment

400

Locations

2

Results

Not posted

Publications

1

Study summary

What the protocol is testing.

This study aims to analyze whether there is a significant difference in the occurrence of postpartum hemorrhage between women who underwent umbilical cord drainage and those who did not. Variables such as estimated blood loss volume, drop in hemoglobin levels, and the need for additional maneuvers or treatments to control hemorrhage will be examined. The research will be conducted under a parallel-group clinical trial design at the Hospital Escuela Universitario. Post-birth umbilical cord drainage may contribute to a lower frequency of postpartum hemorrhage compared to not performing it.

Full detailed description

This is a single-blind, parallel-group, superiority efficacy clinical trial. The intervention involves passive drainage of blood from the umbilical cord immediately after cord clamping and cutting, allowing it to flow into a calibrated drape. The control group receives standard active management of the third stage of labor without cord drainage. The primary objective is to compare postpartum blood loss between the groups. Secondary objectives include comparing pre- and postpartum hemoglobin levels, the need for additional therapeutic interventions (uterotonics, uterine revision, transfusion), incidence of adverse events related to cord management, and maternal satisfaction using the Birth Satisfaction Scale. The study plans to enroll 400 participants (200 per group) over approximately 6 months at a single center.

Interventions

Treatment arms and agents.

PROCEDURE

Umbilical Cord Drainage

Following delivery of the newborn and immediate clamping/cutting of the umbilical cord, the maternal end of the cord is unclamped and allowed to drain passively. The cord is held over a sterile, graduated collection drape (Brass-V Drape) to facilitate the complete, gravity-dependent emptying of the residual placental blood (approximately 50-100 mL) prior to placental delivery. The procedure is completed within 1-3 minutes, after which standard controlled cord traction is applied to assist placental expulsion. This is a non-invasive adjunct to active management of the third stage of labor.

OTHER

Standard Active Management of Third Stage (No Cord Drainage)

This arm receives the standard, evidence-based active management of the third stage of labor, as per institutional protocol, without the specific addition of umbilical cord drainage. The procedure includes immediate administration of a prophylactic uterotonic agent (e.g., oxytocin), delayed cord clamping (as per routine practice), controlled cord traction with counter-pressure on the uterus (Brandt-Andrews maneuver) to assist placental delivery, and uterine massage after placental expulsion. All blood loss is collected and measured in a standard graduated drape. This represents the current standard of care against which the experimental intervention is compared.

Timeline

From registration to results.

  1. First posted

    Feb 10, 2026

  2. Study start

    Feb 15, 2026

  3. Primary completion

    Aug 31, 2026

  4. Study completion

    Sep 30, 2026

  5. Results posted

    Not reported

  6. Registry updated

    Feb 13, 2026

Outcomes

What the study measures.

Primary outcomes

Change in Postpartum Blood Loss Volume

Time frame · From delivery until 24 hours postpartum.

Difference between estimated blood loss volume in the first 24 hours postpartum and an immediate postpartum baseline. Measured using a calibrated drape (Brass-V Drape)

Secondary outcomes

Change in Hemoglobin Levels

Time frame · Pre-delivery and at 6-24 hours postpartum.

Difference between pre-delivery and postpartum (6-24 hours) hemoglobin levels (g/dL).

Need for Additional Therapeutic Interventions

Time frame · First 24 hours postpartum.

Requirement for additional uterotonics, uterine revision, blood transfusion, or surgical procedures to control hemorrhage.

Incidence of Cord Management-Related Adverse Events

Time frame · First 24 hours postpartum

Occurrence of events such as retained placenta, hypovolemic shock.

Maternal Satisfaction Score

Time frame · At 2 hours postpartum.

Maternal satisfaction with the intrapartum experience is measured using the validated Birth Satisfaction Scale-Revised (BSS-R). This is a 10-item self-report questionnaire with three subscales: Quality of Care, Women's Personal Attributes, and Stress Experienced During Labor. Items are scored on a 4-point Likert scale (0-3). The total score ranges from 0 to 30, with a higher total score indicating greater birth satisfaction.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
49 Years
Sex
FEMALE
Healthy volunteers
Yes

Inclusion Criteria: * Pregnant women aged 18-49 years. * Singleton pregnancy. * Gestational age ≥37 weeks. * active labor with cephalic presentation. * Planned for vaginal delivery. * Capable of providing informed consent. Exclusion Criteria: * Planned or emergent cesarean section. * Instrumental delivery (e.g., forceps, vacuum). * Antepartum hemorrhage. * Severe anemia (Hemoglobin \<8 g/dL) or specific hematological disorders (e.g., sickle cell disease, thalassemia, hemophilia, thrombocytopenia \<100,000/µL). * Use of anticoagulant medication. * Non-cephalic fetal presentation (e.g., breech, transverse). * Refusal to participate or inability to provide informed consent.

Study locations

2 registered sites.

Honduras. Showing up to 24 locations stored in the fast local snapshot.

Hospital Escuela

Tegucigalpa, Francisco Morazán Department, Honduras

Instituto Hondureño de Seguridad Social

Tegucigalpa, Francisco Morazán Department, Honduras

Publications

Results and literature.

PMID 39646951 ↗Koshkin ES. A review of the genus Dodia Dyar, 1901 (Lepidoptera: Erebidae, Arctiinae) with description of a new remarkable species from the Russian Far East. Zootaxa. 2024 May 27;5458(1):53-72. doi: 10.11646/zootaxa.5458.1.2.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Oxytocin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsOxytocin trial dashboard →